Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
The company had responded to the agency and carried out the required corrective actions.
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive
The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.
The company has responded to the warning letter and carried out the committed corrections.
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)